Correction to: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

Allergy Asthma Clin Immunol. 2020 May 20:16:38. doi: 10.1186/s13223-020-00435-z. eCollection 2020.

Alexandra Langlois¹, Marie-Hélène Lavergne², Hélène Leroux², Kerstin Killer², Pauline Azzano¹, Louis Paradis^{1

3}, Kathryn Samaan¹, Jonathan Lacombe-Barrios¹, Thomas Eiwegger⁴, Julia Upton⁴, Gordon Sussman⁵, Thomas Poder^{6

7}, Benoît Mâsse^{2

8}, Anne Des Roches^{1

2}, Philippe Bégin^{1

2

3}

¹ 1Department of Allergy and Immunology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC Canada.
² Centre Hospitalier Sainte-Justine Research Center, Montreal, QC Canada.
³ 3Department of Allergy and Immunology, Centre Hospitalier de l'Université de Montréal, 3175 Chemin de la Côte Sainte-Catherine, Montreal, QC H3T1C5 Canada.
⁴ 4Division of Immunology and Allergy, Department of Paediatrics, The Hospital for Sick Children, The University of Toronto, Toronto, ON Canada.
⁵ Gordon Sussman Clinical Research, Toronto, ON Canada.
⁶ 6Department of Management, Evaluation and Health Policy, School of Public Health, Université de Montréal, Montreal, QC Canada.
⁷ 7Research Center of the Institut Universitaire de Santé Mentale de Montréal, Montreal, QC Canada.
⁸ 8School of Public Health, Université de Montréal, Montreal, QC Canada.

Abstract

[This corrects the article DOI: 10.1186/s13223-020-00419-z.].